349 related articles for article (PubMed ID: 35954441)
1. Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies.
Rager T; Eckburg A; Patel M; Qiu R; Gantiwala S; Dovalovsky K; Fan K; Lam K; Roesler C; Rastogi A; Gautam S; Dube N; Morgan B; Nasifuzzaman SM; Ramaswami D; Gnanasekar V; Smith J; Merchant A; Puri N
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954441
[TBL] [Abstract][Full Text] [Related]
2. Resistance to Molecularly Targeted Therapies in Melanoma.
Patel M; Eckburg A; Gantiwala S; Hart Z; Dein J; Lam K; Puri N
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807778
[TBL] [Abstract][Full Text] [Related]
3. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
5. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
[TBL] [Abstract][Full Text] [Related]
7. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
8. A Review of Current and Pipeline Drugs for Treatment of Melanoma.
Natarelli N; Aleman SJ; Mark IM; Tran JT; Kwak S; Botto E; Aflatooni S; Diaz MJ; Lipner SR
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399429
[TBL] [Abstract][Full Text] [Related]
9. Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.
Vennepureddy A; Thumallapally N; Motilal Nehru V; Atallah JP; Terjanian T
J Clin Med Res; 2016 Feb; 8(2):63-75. PubMed ID: 26767073
[TBL] [Abstract][Full Text] [Related]
10. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
12. Multiplying therapies and reducing toxicity in metastatic melanoma.
Massey PR; Prasad V; Figg WD; Fojo T
Cancer Biol Ther; 2015; 16(7):1014-8. PubMed ID: 26016850
[TBL] [Abstract][Full Text] [Related]
13. Looking into a Better Future: Novel Therapies for Metastatic Melanoma.
Villani A; Scalvenzi M; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza SS
Dermatol Ther (Heidelb); 2021 Jun; 11(3):751-767. PubMed ID: 33866515
[TBL] [Abstract][Full Text] [Related]
14. Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.
Gkiala A; Palioura S
Clin Ophthalmol; 2020; 14():3137-3152. PubMed ID: 33116365
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Steininger J; Gellrich FF; Schulz A; Westphal D; Beissert S; Meier F
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804800
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Specenier P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
[No Abstract] [Full Text] [Related]
17. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Gibney GT; Atkins MB
Clin Adv Hematol Oncol; 2015 Jul; 13(7):451-8. PubMed ID: 26353041
[TBL] [Abstract][Full Text] [Related]
19. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]